Difference between revisions of "Ibrutinib (Imbruvica)"
Jump to navigation
Jump to search
m |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Irreversible inhibitor of [http://en.wikipedia.org/wiki/Bruton%27s_tyrosine_kinase Bruton's tyrosine kinase (BTK)], which is an enzyme that participates in the B-cell receptor (BCR) signal cascade and cytokine receptor pathways. BCR signaling is believed to promote cell proliferation, adhesion, and survival in B-cell malignancies. Inhibition of BTK interferes with the processes above, as well as B-cell chemotaxis and trafficking.<ref name=insert>[https://www.imbruvica.com/ | + | Class/mechanism: Irreversible inhibitor of [http://en.wikipedia.org/wiki/Bruton%27s_tyrosine_kinase Bruton's tyrosine kinase (BTK)], which is an enzyme that participates in the B-cell receptor (BCR) signal cascade and cytokine receptor pathways. BCR signaling is believed to promote cell proliferation, adhesion, and survival in B-cell malignancies. Inhibition of BTK interferes with the processes above, as well as B-cell chemotaxis and trafficking.<ref name=insert>[https://www.imbruvica.com/docs/librariesprovider7/default-document-library/prescribing_information.pdf Ibrutinib (Imbruvica) package insert]</ref><ref>[[Media:Ibrutinib.pdf | Ibrutinib (Imbruvica) package insert (locally hosted backup)]]</ref><ref>[http://www.imbruvica.com/ Imbruvica manufacturer's website]</ref> |
<ref>[http://www.pharmacyclics.com/productpipeline1.html Pharmacyclics BTK inhibitor website]</ref><br>Route: PO | <ref>[http://www.pharmacyclics.com/productpipeline1.html Pharmacyclics BTK inhibitor website]</ref><br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 14: | Line 14: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[https://www. | + | *[https://www.imbruvica.com/docs/librariesprovider7/default-document-library/prescribing_information.pdf Ibrutinib (Imbruvica) package insert]<ref name="insert"></ref> |
*[http://chemocare.com/chemotherapy/drug-info/ibrutinib.aspx Ibrutinib (Imbruvica) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/ibrutinib.aspx Ibrutinib (Imbruvica) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/chemotherapy/drug-info/ibrutinib.aspx Ibrutinib (Imbruvica) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/ibrutinib.aspx Ibrutinib (Imbruvica) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/ibrutinib-patient-drug-information Ibrutinib (Imbruvica) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ibrutinib-patient-drug-information Ibrutinib (Imbruvica) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/ibrutinib-patient-drug-information Ibrutinib (Imbruvica) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ibrutinib-patient-drug-information Ibrutinib (Imbruvica) patient drug information (UpToDate)]</ref> | ||
Revision as of 17:59, 16 July 2016
General information
Class/mechanism: Irreversible inhibitor of Bruton's tyrosine kinase (BTK), which is an enzyme that participates in the B-cell receptor (BCR) signal cascade and cytokine receptor pathways. BCR signaling is believed to promote cell proliferation, adhesion, and survival in B-cell malignancies. Inhibition of BTK interferes with the processes above, as well as B-cell chemotaxis and trafficking.[1][2][3]
[4]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- Mantle cell lymphoma
- Waldenström macroglobulinemia
Patient drug information
- Ibrutinib (Imbruvica) package insert[1]
- Ibrutinib (Imbruvica) patient drug information (Chemocare)[5]
- Ibrutinib (Imbruvica) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 11/13/2013: FDA granted accelerated approval "for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy."
- 2/12/2014: FDA granted accelerated approval "for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy."
- 7/28/2014: FDA approval expanded to include patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion).
- 1/29/2015: FDA approval expanded "for the treatment of patients with Waldenström’s macroglobulinemia (WM)."
- 3/4/2016: FDA approval expanded "for the treatment of patients with chronic lymphocytic leukemia (CLL)."
Also known as
CRA-032765, PCI-32765
References
- ↑ 1.0 1.1 1.2 Ibrutinib (Imbruvica) package insert
- ↑ Ibrutinib (Imbruvica) package insert (locally hosted backup)
- ↑ Imbruvica manufacturer's website
- ↑ Pharmacyclics BTK inhibitor website
- ↑ Ibrutinib (Imbruvica) patient drug information (Chemocare)
- ↑ Ibrutinib (Imbruvica) patient drug information (UpToDate)
Categories:
- Drug index
- Chemotherapy
- Oral chemotherapy
- Kinase inhibitors
- BTK inhibitors
- EGFR inhibitors
- ITK inhibitors
- TEC inhibitors
- TXK inhibitors
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications
- Diffuse large B-cell lymphoma medications
- Follicular lymphoma medications
- Mantle cell lymphoma medications
- Waldenström macroglobulinemia medications
- Drugs FDA approved in 2013